ABBVIE INC's ticker is ABBV and the CUSIP is 00287Y109. A total of 3,021 filers reported holding ABBVIE INC in Q1 2022. The put-call ratio across all filers is 0.87 and the average weighting 0.7%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Axel Capital Management, LLC | 59,000 | $9,564,000 | 12.13% |
| swisspartners Advisors Ltd | 102,089 | $16,544,000 | 11.41% |
| PARK CIRCLE Co | 69,250 | $11,226,000 | 9.33% |
| INSPIRION WEALTH ADVISORS, LLC | 249,648 | $40,470,000 | 8.28% |
| Bruce & Co., Inc. | 243,500 | $39,473,000 | 8.07% |
| Apeiron RIA LLC | 90,512 | $15,684,000 | 7.48% |
| BRANDYWINE TRUST CO | 135,101 | $21,901,000 | 7.18% |
| TSFG, LLC | 119,305 | $19,341,000 | 7.01% |
| GROESBECK INVESTMENT MANAGEMENT CORP /NJ/ | 35,294 | $5,722,000 | 6.41% |
| Hall Private Wealth Advisors | 73,551 | $11,923,000 | 6.37% |
| DCF Advisers, LLC | 88,750 | $14,387,000 | 6.30% |
| R.M.SINCERBEAUX CAPITAL MANAGEMENT LLC | 61,250 | $9,929,000 | 6.29% |
| Andrew Hill Investment Advisors, Inc. | 33,565 | $5,441,000 | 6.04% |
| Lynch Asset Management, Inc. | 50,850 | $8,244,000 | 5.89% |
| THORNBURG INVESTMENT MANAGEMENT INC | 2,752,707 | $446,241,000 | 5.85% |
| COLRAIN CAPITAL LLC | 25,550 | $4,142,000 | 5.78% |
| Raub Brock Capital Management LP | 208,015 | $33,721,000 | 5.74% |
| GARLAND CAPITAL MANAGEMENT INC | 51,045 | $8,275,000 | 5.48% |
| RBO & CO LLC | 203,164 | $32,935,000 | 5.38% |
| Hamlin Capital Management, LLC | 933,567 | $151,341,000 | 5.34% |
About ABBVIE INC
AbbVie Inc. is a pharmaceutical company that specializes in the development and commercialization of innovative medicines. The company was founded in 2013 and is headquartered in North Chicago, Illinois. AbbVie's mission is to improve the lives of people around the world by providing them with access to high-quality, safe, and effective medicines.
AbbVie's portfolio of products includes some of the world's most widely used and recognized medicines. These include Humira, a treatment for rheumatoid arthritis, psoriasis, and other autoimmune diseases, and Imbruvica, a treatment for certain types of cancer. The company also has a strong pipeline of new products in development, including treatments for Alzheimer's disease, Parkinson's disease, and other conditions.
AbbVie is committed to sustainability and social responsibility. The company has set ambitious goals to reduce its environmental impact, including reducing greenhouse gas emissions and water usage. AbbVie also supports a range of charitable organizations and initiatives, including those focused on improving access to healthcare and education.
In conclusion, AbbVie Inc. is a leading pharmaceutical company that is dedicated to improving the lives of people around the world. With a strong portfolio of products and a commitment to sustainability and social responsibility, AbbVie is well-positioned for continued success in the years ahead.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists ABBVIE INC's shareholders in Q1 2022. To view ABBVIE INC's shareholder history, click here.